miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms

Ann Hematol. 2021 Nov;100(11):2845-2847. doi: 10.1007/s00277-021-04598-6. Epub 2021 Jul 22.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology
  • Antimetabolites, Antineoplastic / therapeutic use
  • Azacitidine / pharmacology
  • Azacitidine / therapeutic use
  • Cell Line, Tumor
  • Decitabine / pharmacology
  • Decitabine / therapeutic use
  • Drug Resistance, Neoplasm*
  • Gene Expression Regulation, Leukemic / drug effects
  • Humans
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / genetics*
  • MicroRNAs / genetics*
  • THP-1 Cells

Substances

  • Antimetabolites, Antineoplastic
  • MIRN23a microRNA, human
  • MicroRNAs
  • Decitabine
  • Azacitidine